Compare · FONR vs SLNO
FONR vs SLNO
Side-by-side comparison of Fonar Corporation (FONR) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FONR and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 22.1x FONR ($125.1M).
- Over the past year, FONR is up 31.9% and SLNO is down 31.8% - FONR leads by 63.7 points.
- SLNO has been more active in the news (39 items in the past 4 weeks vs 18 for FONR).
- SLNO has more recent analyst coverage (12 ratings vs 0 for FONR).
- Company
- Fonar Corporation
- Soleno Therapeutics Inc.
- Price
- $19.10+0.03%
- $53.02+0.08%
- Market cap
- $125.1M
- $2.76B
- 1M return
- +0.90%
- +0.76%
- 1Y return
- +31.91%
- -31.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1981
- 2014
- News (4w)
- 18
- 39
- Recent ratings
- 0
- 12
Fonar Corporation
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest FONR
- SEC Form 4 filed by Director Turk Richard E.
- SEC Form 3 filed by new insider Turk Richard E.
- SEC Form 4 filed by EVP/COO/Acting PFO Bonanni Luciano B
- EVP/COO Bonanni Luciano B was granted 47,226 units of FONAR CORPORATION COMMON STOCK, increasing direct ownership by 2,029% to 49,553 units (SEC Form 4)
- New insider Bonanni Luciano B claimed ownership of 2,327 units of FONAR CORPORATION COMMON STOCK (SEC Form 3)
- SEC Form 4 filed by President/CEO/Treasurer Damadian Timothy Raymond
- President/CEO/Treasurer Damadian Timothy Raymond was granted 26,000 units of FONAR CORPORATION COMMON STOCK and transferred by will 36,359 units of FONAR CORPORATION COMMON STOCK), increasing direct ownership by 559% to 79,059 units (SEC Form 4)
- New insider Damadian Timothy Raymond claimed ownership of 12,000 units of FONAR CORPORATION COMMON STOCK (SEC Form 3)
- Large owner Shane Hilary bought $4,113,298 worth of shares (215,336 units at $19.10) (SEC Form 4)
- SEC Form S-8 POS filed by Fonar Corporation
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)